Table 3. Prevalence and incidence studies investigating neuromyelitis optica spectrum disorder.
| Reference | Region/country | Crude prevalence (95% CI/100,000) | Crude incidence (95% CI/100,000) |
|---|---|---|---|
| 2 | Cuba | 0.52 (0.39–0.068) | 0.053 (0.04–0.068) |
| 3,19 | North America | 2.3 (0.6–3.9) in Martinique | 0.19 (0.15–0.23) |
| Martinique & Guadeloupe | 2.9 (1.1–4.7) in Guadeloupe | ||
| 4 | United Kingdom | 0.72 | 0.08 (0.03–0.16) |
| 5 | United States | 3.9 | 0.7 |
| 7 | Malaysia | 1.99 (1.09–3.35) | - |
| 8 | Wales South East | 1.96 (1.22–2.97) | - |
| 9 | Denmark | 4.4 (3.1–5.7) | 0.4 (0.3–0.54) |
| 13 | India | 2.6 | - |
| 14 | Iran | 1.9 (1.6–2.3) | - |
| 17 | Japan | 4.1 (2.2–6.9) | - |
CI = confidence interval.